Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

BRAF inhibitors and melanoma.

Flaherty KT.

Cancer J. 2011 Nov-Dec;17(6):505-11. doi: 10.1097/PPO.0b013e31823e5357. Review.

PMID:
22157295
2.

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G.

Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Review.

3.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
4.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
5.

BRAF in melanoma: current strategies and future directions.

Salama AK, Flaherty KT.

Clin Cancer Res. 2013 Aug 15;19(16):4326-34. doi: 10.1158/1078-0432.CCR-13-0779. Epub 2013 Jun 14. Review.

6.

MAP kinase signaling and inhibition in melanoma.

Sullivan RJ, Flaherty K.

Oncogene. 2013 May 9;32(19):2373-9. doi: 10.1038/onc.2012.345. Epub 2012 Sep 3. Review.

PMID:
22945644
7.

Novel inhibitors in the treatment of metastatic melanoma.

Kalinsky K, Haluska FG.

Expert Rev Anticancer Ther. 2007 May;7(5):715-24. Review.

PMID:
17492934
8.

Targeting BRAF in melanoma: biological and clinical challenges.

MandalĂ  M, Voit C.

Crit Rev Oncol Hematol. 2013 Sep;87(3):239-55. doi: 10.1016/j.critrevonc.2013.01.003. Epub 2013 Feb 15. Review.

PMID:
23415641
9.

The role of the PI3K-AKT pathway in melanoma.

Davies MA.

Cancer J. 2012 Mar-Apr;18(2):142-7. doi: 10.1097/PPO.0b013e31824d448c. Review.

PMID:
22453015
10.

The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Haluska F, Pemberton T, Ibrahim N, Kalinsky K.

Semin Oncol. 2007 Dec;34(6):546-54. Review.

PMID:
18083378
11.

Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.

Lai F, Jin L, Gallagher S, Mijatov B, Zhang XD, Hersey P.

Adv Pharmacol. 2012;65:27-43. doi: 10.1016/B978-0-12-397927-8.00002-6. Review.

PMID:
22959022
12.

Adaptive resistance to RAF inhibitors in melanoma.

Kugel CH 3rd, Aplin AE.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1032-8. doi: 10.1111/pcmr.12264. Epub 2014 Jun 6. Review.

13.

Biological challenges of BRAF inhibitor therapy.

Puzanov I, Burnett P, Flaherty KT.

Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Epub 2011 Feb 16. Review.

14.

Emerging Raf inhibitors.

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.

Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Review.

PMID:
19715444
15.

Narrative review: BRAF opens the door for therapeutic advances in melanoma.

Flaherty KT.

Ann Intern Med. 2010 Nov 2;153(9):587-91. doi: 10.7326/0003-4819-153-9-201011020-00008. Review.

PMID:
21041578
16.

BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.

Rahman MA, Salajegheh A, Smith RA, Lam AK.

Curr Cancer Drug Targets. 2014;14(2):128-43. Review.

PMID:
24446739
17.

Emerging BRAF inhibitors for melanoma.

Sabbatino F, Wang Y, Wang X, Ferrone S, Ferrone CR.

Expert Opin Emerg Drugs. 2013 Dec;18(4):431-43. doi: 10.1517/14728214.2013.842975. Epub 2013 Sep 27. Review.

PMID:
24073999
18.

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Welsh SJ, Rizos H, Scolyer RA, Long GV.

Eur J Cancer. 2016 Jul;62:76-85. doi: 10.1016/j.ejca.2016.04.005. Epub 2016 May 24. Review.

PMID:
27232329
19.

Targeted therapy for melanoma: rational combinatorial approaches.

Kwong LN, Davies MA.

Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18. Review.

PMID:
23416974
20.

BRAF inhibitors in cancer therapy.

Hertzman Johansson C, Egyhazi Brage S.

Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8. Review.

PMID:
24325952

Supplemental Content

Support Center